|
|
Post by agedhippie on Feb 21, 2019 9:35:49 GMT -5
It's tricky. For corrections it would be 4u, but for meals I don't know whether 8u or 12u would be better. Typically I take about 7u for a meal so I think probably the 12u based on Afrezza to RAA scaling. |
|
|
|
Post by sportsrancho on Feb 21, 2019 9:36:59 GMT -5
|
|
|
|
Post by harryx1 on Feb 21, 2019 10:31:13 GMT -5
|
|
|
|
Post by mango on Feb 21, 2019 10:40:19 GMT -5
|
|
|
|
Post by liane on Feb 21, 2019 11:32:30 GMT -5
Folks - I don't want to lock this thread. Please stop speculating, commenting if anyone is a short, basher, etc. The mods try to ensure that the rules of the board are enforced, but labeling another poster one way or another is a personal attack.
|
|
|
|
Post by sportsrancho on Feb 21, 2019 11:56:49 GMT -5
One Drop's favorable results. Among Type 2 diabetes patients using an injectable or inhalable bolus insulin, use of the One Drop Mobile platform was associated with a −.93 percent improvement in absolute A1c, according to data presented by One Drop researchers at the 2019 Advanced Technologies & Treatments for Diabetes conference in Berlin. "We are thrilled with the results of our IRB-approved, investigator-initiated, pragmatic, randomized controlled trial measuring the A1c impact of One Drop with Afrezza compared to One Drop with injectable bolus insulin," Jeff Dachis, CEO and founder of One Drop, said in a statement. "As indicated in our significant body of peer-reviewed evidence, A1c significantly improves when people have digital tools and reliable resources to understand how to best use medications. It's very exciting to see these kinds of results, particularly with an innovative product like Afrezza." |
|
|
|
Post by harryx1 on Feb 21, 2019 12:03:44 GMT -5
sportsranchoI'm guessing she is giving us more info than what was in the article: Afrezza + OneDrop = .93% reduction vs. RAA + OneDrop = .23% which equals a .70% difference
|
|
|
|
Post by oldfishtowner on Feb 21, 2019 13:03:11 GMT -5
400 patients. 0.7 drop in A1c vs RAA. A superiority trial if ever there was one. Is it enough for a label change?
|
|
|
|
Post by epc1355 on Feb 21, 2019 13:47:19 GMT -5
0.7 total  , or 0.7 percent  |
|
|
|
Post by akemp3000 on Feb 21, 2019 14:07:20 GMT -5
Regardless of the minutia over the numbers, this statement summarizes the study nicely and appears to be irrefutable. Please pay particular notice to the word "significantly".
"By delivering a time-action profile closer to that of physiologic insulin action, post-prandial glucose levels and other markers of glycemic control were significantly improved compared to injected insulin in meal-challenge tests in patients with type 2 diabetes," said David Kendall, Chief Medical Officer of MannKind.
|
|
|
|
Post by epc1355 on Feb 21, 2019 14:25:05 GMT -5
It must be absolute to be significant, right?? A1c going from 8 to 7.94 (0.7%) can’t be significant. 8 to 7.3 could be.
|
|
|
|
Post by john12345 on Feb 21, 2019 14:44:47 GMT -5
It must be absolute to be significant, right?? A1c going from 8 to 7.94 (0.7%) can’t be significant. 8 to 7.3 could be. 8% - 0.7% = 7.3%, so from 8 to 7.3 |
|
|
|
Post by peppy on Feb 21, 2019 14:55:11 GMT -5
|
|
|
|
Post by akemp3000 on Feb 21, 2019 16:26:16 GMT -5
Dr. David Kendall was the Chief Scientific and Medical Officer for the American Diabetes Association. He left his position of VP for Global Medical Affairs for Lilly Diabetes to join Mannkind. If he says the results are significant, they're significant and without question mean that Afrezza outperforms competitors. Quantifying the degree is getting lost in the weeds but what the heck, a message board is a really good place for this  |
|
|
|
Post by agedhippie on Feb 21, 2019 18:32:43 GMT -5
sportsrancho I'm guessing she is giving us more info than what was in the article: Afrezza + OneDrop = .93% reduction vs. RAA + OneDrop = .23% which equals a .70% difference She is ex-OneDrop so she may know the full results. Failing that hopefully they give them in the results call. |
|
, or 0.7 percent 
